Santarus

Santarus is a bit controlling, but in this case it's okay. Santarus' flagship drug Glumetza improves glycemic control for type 2 diabetes patients and is marketed through a partnership with Depomed. It markets a similar drug, Cycloset, also to improve glycemic control for type 2 diabetes, through a distribution and license agreement with S2 Therapeutics and Veroscience. Santarus' lead product used to be Zegerid, a modified version of omeprazole, the proton pump inhibitor found in AstraZeneca's best-selling Prilosec for heartburn. But when Zegerid's patent ran out and its sales dropped, Santarus moved on to more fruitful ground. Other candidates include treatments for ulcerative colitis and angioedema.